Vanguard Capital Management’s Phathom Pharmaceuticals PHAT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$20M Buy
2,735,113
+78,169
+3% +$737K ﹤0.01% 2403
2026
Q2
$28.8M Buy
2,656,944
+73,308
+3% +$836K ﹤0.01% 2248
2026
Q1
$28.7M Buy
+2,583,636
New +$32.6M ﹤0.01% 2156

Other funds holding PHAT

Vanguard Capital Management's PHAT Position: Q3 2026 in Review

Vanguard Capital Management increased its Phathom Pharmaceuticals (PHAT) stake by 2.9% in Q3 2026, buying an estimated $737K and bringing the position to 2,735,113 shares worth $20M. The position accounts for ﹤0.01% of the portfolio, ranked #2403.

Vanguard Capital Management first reported a position in PHAT in Q1 2026 and has held it in 3 quarters since. The position peaked at $28.8M in Q2 2026. 161 funds tracked by Wall St. Rank hold PHAT as of Q3 2026.

  • Vanguard Capital Management held 2,735,113 shares of Phathom Pharmaceuticals worth $20M as of Q3 2026.
  • Vanguard Capital Management bought 78,169 Phathom Pharmaceuticals shares in Q3 2026, an estimated $737K.
  • Phathom Pharmaceuticals made up ﹤0.01% of Vanguard Capital Management's portfolio in Q3 2026, its #2403 holding.
  • Vanguard Capital Management first reported a position in Phathom Pharmaceuticals in Q1 2026 and has held it in 3 quarters since.
  • Vanguard Capital Management's Phathom Pharmaceuticals position peaked at $28.8M in Q2 2026.
  • 161 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q3 2026.

Based on Vanguard Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.